Collaboration with Sohin Genetics
GENinCode Plc has announced a commercial agreement with Sohin Genetics in Mexico to distribute its CARDIO inCode-Score® Polygenic Risk Score test, aimed at predicting and preventing coronary heart disease. This collaboration targets Mexico's significant cardiovascular disease market, estimated at USD $4.3 billion, where heart disease is the leading cause of death. Sohin Genetics will promote and market the test across its network of hospitals and clinics, leveraging GENinCode's SITAB international reporting system. This expansion into Mexico follows GENinCode's recent collaboration with AMPAC, further strengthening its presence in the growing cardiovascular disease prevention sector.
Select text to share a quote on X · sign in to keep highlights & notes in your GENI notes
GENinCode Plc (AIM: GENI), the Oxford based predictive genetics company focused on the prevention of cardiovascular disease ("CVD") and risk assessment of ovarian cancer, announces today a collaboration with Sohin Genetics, Mexico to distribute the CARDIO inCode-Score® Polygenic Risk Score ("PRS") test for the prevention of coronary heart disease ("CHD" or "heart disease").
This announcement follows the recent collaboration between GENinCode and "AMPAC" (Mexican Association for the prevention of Atherosclerosis) dedicated to research, education and promotion of healthy lifetstyles to combat atherosclerosis and heart disease in Mexico.
Sohin Genetics provide integrated healthcare services, especially in diagnostics, to deliver precision medicine access across their network of hospitals and clinics. Sohin Genetics will commercially promote and market CARDIO inCode-Score in the Mexican market including training, sample handling and ordering via the GENinCode 'SITAB' international reporting system. Mexico has a population of over 130 million with an estimated cardiovascular disease market of USD$ 4.3 billion with coronary heart disease the leading cause of death.
CARDIO inCode-Score® (PRS)
CARDIO inCode-Score is a clinically validated, commercially available polygenic risk score (PRS) based on DNA extracted from a simple saliva or blood sample. The extracted DNA is scored to identify an individual's inherited genetic risk of heart disease thereby enabling prevention through lifestyle change and/or therapeutic treatment. The test has been designed and optimized for population-based risk prediction and primary prevention of heart disease and is being made available at affordable pricing to international healthcare systems.
By integrating CARDIO inCode-Score® into existing clinical pathways, healthcare providers can more accurately identify individuals at heightened 'lifetime risk' of heart disease and personalise treatment and prevention strategies. This preventive approach reduces the incidence of severe cardiovascular events, such as heart attacks and strokes, and mitigates the economic costs associated with long-term heart disease care. It represents a significant step to improving public health outcomes and particularly in addressing the global burden of cardiovascular disease.
Matthew Walls, GENinCode Chief Executive Officer said; "We are delighted to announce this latest distribution agreement with Sohin Genetics to sell CARDIO inCode-Score in Mexico. The collaboration will extend our reach into this growing cardiovascular disease market and allow us to consider other tests for distribution in the region."
- British Heart Foundation - www.bhf.org.uk - Statistics
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.